What is the best medicine for liver disease?

1. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733–46. doi: 10.1016/j.cld.2008.07.007. vii. [PubMed] [CrossRef] [Google Scholar]

2. Graudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230(2):165–71. [PubMed] [Google Scholar]

3. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6. [PubMed] [Google Scholar]

4. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, et al. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon. 2013;13(8):e23539. doi: 10.5812/hepatmon.11290. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, et al. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf. 2008;31(3):261–70. [PubMed] [Google Scholar]

6. Imani F, Safari S. “Pain Relief is an Essential Human Right”, We Should be Concerned about It. Anesth Pain Med. 2011;1(2):55–7. [PMC free article] [PubMed] [Google Scholar]

7. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5(2):157–67. [PubMed] [Google Scholar]

8. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002;22(2):123–36. doi: 10.1055/s-2002-30099. [PubMed] [CrossRef] [Google Scholar]

9. Rahimzadeh P, Safari S, Faiz SH, Alavian SM. Anesthesia for patients with liver disease. Hepat Mon. 2014;14(7) doi: 10.5812/hepatmon.19881. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61. doi: 10.1007/s00228-008-0553-z. [PubMed] [CrossRef] [Google Scholar]

11. Safari S, Motavaf M, Seyed Siamdoust SA, Alavian SM. Hepatotoxicity of Halogenated Inhalational Anesthetics. Iran Red Crescent Med J. 2014;16(9) doi: 10.5812/ircmj.20153. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Mohseni M, Safari S, Alavian SM. Volatile anesthetics in ischemic liver injury: enemy or friend? Hepat Mon. 2014;14(6) doi: 10.5812/hepatmon.19880. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet. 1979;4(6):423–32. [PubMed] [Google Scholar]

14. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–45. [PubMed] [Google Scholar]

15. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991;13(4):786–95. [PubMed] [Google Scholar]

16. Debinski HS, Lee CS, Danks JA, Mackenzie PI, Desmond PV. Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108(5):1464–9. [PubMed] [Google Scholar]

17. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005;28(3):227–40. [PubMed] [Google Scholar]

18. Arnman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg). 1978;25(4):283–6. [PubMed] [Google Scholar]

19. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl. 1979;624:99–105. [PubMed] [Google Scholar]

20. Alimian M, Pournajafian A, Kholdebarin A, Ghodraty M, Rokhtabnak F, Yazdkhasti P. Analgesic effects of paracetamol and morphine after elective laparotomy surgeries. Anesth Pain Med. 2014;4(2) doi: 10.5812/aapm.12912. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12(2):133–41. [PubMed] [Google Scholar]

22. Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. BMC Med. 2007;5:13. doi: 10.1186/1741-7015-5-13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther. 2007;26(2):283–90. doi: 10.1111/j.1365-2036.2007.03368.x. [PubMed] [CrossRef] [Google Scholar]

24. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, Spanish Collaborative Study Group on Therapeutic Management of Liver D. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59(1):71–6. doi: 10.1007/s00228-003-0586-2. [PubMed] [CrossRef] [Google Scholar]

25. Khalid SK, Lane J, Navarro V, Garcia-Tsao G. Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009;7(9):994–9. doi: 10.1016/j.cgh.2009.04.015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93. doi: 10.1001/jama.296.1.87. [PubMed] [CrossRef] [Google Scholar]

27. American Liver Foundation The American Liver Foundation Issues Warning on Dangers of Excess Acetaminophen. American Liver Foundation. 2006 Available from: http://www.liverfoundation.org/downloads/alf_download_39.pdf.

28. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–8. doi: 10.4065/mcp.2009.0534. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Schoene B, Fleischmann RA, Remmer H, von Oldershausen HF. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972;4(2):65–73. [PubMed] [Google Scholar]

30. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol. 1984;27(3):291–6. [PubMed] [Google Scholar]

31. Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol. 2012;18(24):3035–49. doi: 10.3748/wjg.v18.i24.3035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology. 1993;104(3):869–76. [PubMed] [Google Scholar]

33. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17(6):530–48. [PubMed] [Google Scholar]

34. Arroyo V, Gines P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med. 1986;81(2B):104–22. [PubMed] [Google Scholar]

35. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330(2):156–60. [PubMed] [Google Scholar]

36. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69:165–75. [PubMed] [Google Scholar]

37. Perez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 1984;26(1):72–80. [PubMed] [Google Scholar]

38. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563–8. [PMC free article] [PubMed] [Google Scholar]

39. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:21–8. doi: 10.1111/j.1365-2036.2007.03509.x. [PubMed] [CrossRef] [Google Scholar]

40. De Ledinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut. 1999;44(2):270–3. [PMC free article] [PubMed] [Google Scholar]

41. Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am J Gastroenterol. 2002;97(8):2033–9. doi: 10.1111/j.1572-0241.2002.05847.x. [PubMed] [CrossRef] [Google Scholar]

42. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90(1):182–7. [PubMed] [Google Scholar]

43. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979;48(6):895–900. doi: 10.1210/jcem-48-6-895. [PubMed] [CrossRef] [Google Scholar]

44. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983;13(3):271–8. [PubMed] [Google Scholar]

45. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-Del-Arbol L, Gines P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–87. doi: 10.1002/hep.20595. [PubMed] [CrossRef] [Google Scholar]

46. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci. 1987;294(3):168–74. [PubMed] [Google Scholar]

47. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology. 1999;116(5):1167–75. [PubMed] [Google Scholar]

48. Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol. 2002;135(4):891–900. doi: 10.1038/sj.bjp.0704528. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S37–42. [PubMed] [Google Scholar]

50. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29(3):289–97. [PMC free article] [PubMed] [Google Scholar]

51. Hajiesmaeili MR, Safari S. Pain management in the intensive care unit: do we need special protocols? Anesth Pain Med. 2012;1(4):237–8. doi: 10.5812/aapm.4523. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Eydi M, Golzari SE, Aghamohammadi D, Kolahdouzan K, Safari S, Ostadi Z. Postoperative Management of Shivering: A Comparison of Pethidine vs. Ketamine. Anesth Pain Med. 2014;4(2) doi: 10.5812/aapm.15499. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Imani F, Faiz HR, Sedaghat M, Hajiashrafi M. Effects of adding ketamine to fentanyl plus acetaminophen on postoperative pain by patient controlled analgesia in abdominal surgery. Anesth Pain Med. 2014;4(1) doi: 10.5812/aapm.12162. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83–4. [PubMed] [Google Scholar]

55. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997;61(6):655–61. doi: 10.1016/S0009-9236(97)90100-4. [PubMed] [CrossRef] [Google Scholar]

56. Moradi M, Esmaeili S, Shoar S, Safari S. Use of oxycodone in pain management. Anesth Pain Med. 2012;1(4):262–4. doi: 10.5812/aapm.4529. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24. doi: 10.1016/S0025-6196(11)60750-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953–64. [PubMed] [Google Scholar]

59. Franz CC, Egger S, Born C, Ratz Bravo AE, Krahenbuhl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68(2):179–88. doi: 10.1007/s00228-011-1105-5. [PubMed] [CrossRef] [Google Scholar]

60. Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012;32(5):859–66. doi: 10.1111/j.1478-3231.2011.02739.x. [PubMed] [CrossRef] [Google Scholar]